Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-18

Study Completion Date

2023-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antibody-mediated rejection is now recognized as the first cause of long-term kidney transplant loss. This type of rejection is mediated by the presence of graft-specific antibodies, usually directed against HLA (Human Leukocyte Antigens), called DSA (Donor Specific Antibody).

De novo DSA (ie, post-transplantation) is detected in approximately 20% of transplant recipients in the first five years, and is a major risk factor for antibody mediated rejection and graft loss.

All anti-HLA antibodies therefore do not have the same pathogenicity. Some teams have shown that the detection of IgG3 anti-HLA by cytometry is associated with a higher risk of humoral rejection but these results have not been confirmed by others. One of the limitations of the cytometry by Luminex technique is that it only informs the detection of each subclass but does not allow analysis of the distribution of the different subclasses of a DSA.

A method has been developed for the relative detection and quantification of different subclasses of the DSA using the mass spectrometry technique and will be tested during this study. This new quantification method therefore opens up the prospect of studying whether, not only the presence but especially the distribution of IgG subclasses, in particular IgG3, could constitute a reliable and robust marker of humoral rejection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated Rejection in Kidney Transplantation

NCT03098238

Renal Transplantation

COMPLETED NA

Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level

NCT03861962

Organ Transplantation

UNKNOWN

DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients

NCT04368962

Antibody-mediated Rejection

UNKNOWN

DE NOVO DONOR SPECIFIC ANTIBODIES AFTER KIDNEY TRANSPLANTATION: SINGLE-CENTER RETROSPECTIVE STUDY

NCT06425497

Kidney Transplant; Complications Immunosuppression

COMPLETED

Immunization Anti HLA in the Liver Transplant Recipients (DSATH)

NCT02556879

Liver Transplantation Graft Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antibody-mediated rejection is now recognized as the first cause of long-term kidney transplant loss. This type of rejection is mediated by the presence of graft-specific antibodies, usually directed against HLA (Human Leukocyte Antigens), called DSA (Donor Specific Antibody). It results from the interaction between DSA and HLA present on the surface of graft endothelial cells, complement activation, endothelial cell activation and recruitment of inflammatory cells within the renal microcirculation leading to a graft dysfunction.

De novo DSA (ie, post-transplantation) is detected in approximately 20% of transplant recipients in the first five years, and is a major risk factor for antibody mediated rejection and graft loss. However, the presence of a DSA is not always associated with humoral rejection.

All anti-HLA antibodies therefore do not have the same pathogenicity. The antibody titre (assessed by the fluorescence average (MFI) on Luminex beads) is involved in the risk of rejection but is far from explaining the disparities in clinical evolution.

DSA are mainly IgG of different subclasses whose distribution could have a major impact on their pathogenicity. Indeed, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) functions differ according to IgG subclass. IgG3 is the subclass that has the greatest potential for complement activation followed by IgG1. IgG3 and IgG1 are also the two subclasses with the best affinities for the FcγRIIIa activating receptor for ADCC mediated by Natural Killer (NK) cells.

Some teams have shown that the detection of IgG3 anti-HLA by cytometry is associated with a higher risk of humoral rejection but these results have not been confirmed by others. One of the limitations of the cytometry by Luminex technique is that it only informs the detection of each subclass but does not allow analysis of the distribution of the different subclasses of a DSA.

A method has been developed for the relative detection and quantification of different subclasses of the DSA using the mass spectrometry technique and will be tested during this study. This new quantification method therefore opens up the prospect of studying whether, not only the presence but especially the distribution of IgG subclasses, in particular IgG3, could constitute a reliable and robust marker of humoral rejection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antibody-mediated Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient with kidney transplant

Blood sample will be took from subjects during this research

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Patients over 18 years old
* Renal transplant patients followed at the University Hospital of Montpellier presenting a DSA de novo during follow-up.
* Affiliation or beneficiary of a social security scheme.

* Patients who consented to the collection of a plasma sample on graft biopsy day and use in future programs (Collection DC-2014-2328)
* Collection of non-opposition to participate in the study

* Eligible for graft biopsy for humoral-mediated rejection (according to Banff 2015 classification) (Appendix 1)
* Collection of non-opposition to participate in the study
* Signature of informed consent to participate in the collection of a plasma sample on graft biopsy day and use in future programs (Collection DC-2014-2328)

Exclusion Criteria

* Pregnant or lactating women according to Article L1121 5 of the health public Code
* Vulnerable persons according to article L1121-6 of the health public Code
* Major persons placed under guardianship or curator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No